Here, the authors show that lymphoma-associated C-terminal mutations in MEF2B impair its phosphorylation, leading to increased stability and transcriptional activity to promote B-cell lymphomagenesis.

One July evening, Allison Rosenthal, D.O., received a flurry of texts with exclamations like, "Yo, my doctor friend is famous ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. There are several types of DLBCL, each with their own treatment options. Diffuse large B-cell lymphoma (DLBCL ...

Remission means that your lymphoma has been either eliminated or reduced. When the tumor is completely gone, healthcare providers call it "complete remission." When the tumor has been largely reduced ...

In winning European approval, Ordspono became Regeneron’s first “bispecific” antibody drug, a class that has been in the spotlight in recent years as an alternative to costly and cumbersome CAR-T cell ...

The Phase I/II EPCORE NHL-1 trial is a comprehensive study designed to assess the safety and preliminary efficacy of subcutaneous epcoritamab in various types of non-Hodgkin’s lymphoma, including ...

“This clinical trial is not studying a treatment, but instead it is surveying young people who have survived lymphoma to figure out how they handle the rigors of transitioning to adulthood while ...

Hodgkin lymphoma is a type of lymphoma (a cancer originating from white blood cells called lymphocytes) characterised by the presence of a type of cell called the Reed Sternberg cell. Symptoms ...

Emily Hodgkin is Assistant Editor and Head of Lifestyle at Express US. She covers lifestyle and frequently writes about the British Royal Family, style and beauty, viral trends and real-life ...